Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.

TAK-279 effectively reduces psoriasis symptoms and is safe.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

A patient's grey hair regained color during treatment with adalimumab.

The compound zishenqing formula is effective and safe for treating mild to moderate systemic lupus erythematosus.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.